Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:35:35.959Z.
Calculation as of: 2026-10-06T13:35:35.959Z.
Quote observation: 2026-10-06T13:35:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 098b8cc383d7c70bc2f58c50adf850e5cd93194028a42938ba247026a8eec5c0
PE RATIO
N/A
Market Cap
$1.72B
PE Ratio
44.53
TTM Avg
147.35
3Y Avg
147.35
5Y Avg
147.35
Market Cap
$1.53B
PE Ratio
145.19
TTM Avg
152.77
3Y Avg
83.75
5Y Avg
83.75
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alphatec Holdings, Inc. (ATEC) | $1.67B | N/A | N/A | N/A | N/A |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.67B | 15.86 | 29.99 | 47.18 | 47.18 |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.69B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | N/A | 23.72 | 50.63 | 57.39 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.74B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.58B | N/A | 174.30 | 183.89 | 183.89 |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.72B | 44.53 | 147.35 | 147.35 | 147.35 |
| Innoviva, Inc. (INVA)vs › | $1.53B | 5.04 | 13.44 | 25.81 | 17.64 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.53B | 145.19 | 152.77 | 83.75 | 83.75 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.49B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
33.1
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$10.83
Forward EPS (Est.)
$0.33
Forward P/E
33.15
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
